Update of neurotrophic factors in neurobiology of addiction and future directions

Neurobiology of Disease

Volumn 97, Issue , 2017, Pages 189-200

  Koskela, Maryna ^a   Bäck, Susanne ^c   Võikar, Vootele ^b   Richie, Christopher T ^c   Domanskyi, Andrii ^a   Harvey, Brandon K ^c   Airavaara, Mikko ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; BRAIN DERIVED NEUROTROPHIC FACTOR; COMPLEMENTARY RNA; DOPAMINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; METHAMPHETAMINE; MICRORNA; MORPHINE; NERVE GROWTH FACTOR;

BEHAVIORAL SCIENCE; BRAIN REGION; CRISPR CAS SYSTEM; DRUG CRAVING; DRUG DEPENDENCE; DRUG SEEKING BEHAVIOR; EXPERIMENTAL ANIMAL; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HUMAN; NEUROBIOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; REWARD; TRANSGENIC RAT; ANIMAL; METABOLISM;

ANIMALS; HUMANS; NERVE GROWTH FACTORS; SUBSTANCE-RELATED DISORDERS;

EID: 84969549238     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2016.05.010     Document Type: Review

References (187)

1. Ahmadiantehrani, S., et al. GDNF is a novel ethanol-responsive gene in the VTA: implications for the development and persistence of excessive drinking. Addict. Biol. 19 (2014), 623–633.
2. Airaksinen, M.S., Saarma, M., The GDNF family: signalling, biological functions and therapeutic value. Nat. Rev. Neurosci. 3 (2002), 383–394.
3. Airavaara, M., et al. Increased extracellular dopamine concentrations and FosB/DeltaFosB expression in striatal brain areas of heterozygous GDNF knockout mice. Eur. J. Neurosci. 20 (2004), 2336–2344.
4. Airavaara, M., et al. Effects of repeated morphine on locomotion, place preference and dopamine in heterozygous glial cell line-derived neurotrophic factor knockout mice. Genes Brain Behav. 6 (2007), 287–298.
5. Airavaara, M., et al. Endogenous GDNF in ventral tegmental area and nucleus accumbens does not play a role in the incubation of heroin craving. Addict. Biol. 16 (2011), 261–272.
6. Airavaara, M., et al. Identification of novel GDNF isoforms and cis-antisense GDNFOS gene and their regulation in human middle temporal gyrus of Alzheimer disease. J. Biol. Chem. 286 (2011), 45093–45102.
7. Airavaara, M., et al. Neurorestoration. Parkinsonism Relat. Disord. 18:Suppl. 1 (2012), S143–S146.
8. Akagi, K., et al. Cre-mediated somatic site-specific recombination in mice. Nucleic Acids Res. 25 (1997), 1766–1773.
9. Alboni, S., et al. Fluoxetine effects on molecular, cellular and behavioral endophenotypes of depression are driven by the living environment. Mol. Psychiatry, 2015 (in press).
10. Alexandrov, V., et al. Reprint of: high throughput analysis of behavior for drug discovery. Eur. J. Pharmacol. 753 (2015), 127–134.
11. Altar, C.A., et al. Brain-derived neurotrophic factor augments rotational behavior and nigrostriatal dopamine turnover in vivo. Proc. Natl. Acad. Sci. U. S. A. 89 (1992), 11347–11351.
12. Austin, C.P., et al. The knockout mouse project. Nat. Genet. 36 (2004), 921–924.
13. Auwerx, J., et al. The European dimension for the mouse genome mutagenesis program. Nat. Genet. 36 (2004), 925–927.
14. Bahi, A., Dreyer, J.L., Striatal modulation of BDNF expression using microRNA124a-expressing lentiviral vectors impairs ethanol-induced conditioned-place preference and voluntary alcohol consumption. Eur. J. Neurosci. 38 (2013), 2328–2337.
15. Barak, S., et al. Glial cell line-derived neurotrophic factor (GDNF) is an endogenous protector in the mesolimbic system against excessive alcohol consumption and relapse. Addict. Biol. 20 (2015), 629–642.
16. Beckers, J., et al. Towards better mouse models: enhanced genotypes, systemic phenotyping and envirotype modelling. Nat. Rev. Genet. 10 (2009), 371–380.
17. Bespalov, M.M., et al. Heparan sulfate proteoglycan syndecan-3 is a novel receptor for GDNF, neurturin, and artemin. J. Cell Biol. 192 (2011), 153–169.
18. Boger, H.A., et al. A partial GDNF depletion leads to earlier age-related deterioration of motor function and tyrosine hydroxylase expression in the substantia nigra. Exp. Neurol. 202 (2006), 336–347.
19. Bolanos, C.A., et al. Phospholipase C gamma in distinct regions of the ventral tegmental area differentially regulates morphine-induced locomotor activity. Synapse 56 (2005), 166–169.
20. Bossert, J.M., et al. The reinstatement model of drug relapse: recent neurobiological findings, emerging research topics, and translational research. Psychopharmacology 229 (2013), 453–476.
21. Branchi, I., et al. Antidepressant treatment outcome depends on the quality of the living environment: a pre-clinical investigation in mice. PLoS ONE, 8, 2013, e62226.
22. Buehr, M., et al. Capture of authentic embryonic stem cells from rat blastocysts. Cell 135 (2008), 1287–1298.
23. Burke, R.E., GDNF as a candidate striatal target-derived neurotrophic factor for the development of substantia nigra dopamine neurons. J. Neural Transm. Suppl., 41, 2006, 5.
24. Carnicella, S., Ron, D., GDNF–a potential target to treat addiction. Pharmacol. Ther. 122 (2009), 9–18.
25. Carnicella, S., et al. GDNF is a fast-acting potent inhibitor of alcohol consumption and relapse. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 8114–8119.
26. Cass, W.A., et al. Augmented methamphetamine-induced overflow of striatal dopamine 1 day after GDNF administration. Brain Res. 827 (1999), 104–112.
27. Chandrasekar, V., Dreyer, J.L., microRNAs miR-124, let-7d and miR-181a regulate cocaine-induced plasticity. Mol. Cell. Neurosci. 42 (2009), 350–362.
28. Chao, M.V., Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat. Rev. Neurosci. 4 (2003), 299–309.
29. Chapman, K.M., et al. Targeted germline modifications in rats using CRISPR/Cas9 and spermatogonial stem cells. Cell Rep. 10 (2015), 1828–1835.
30. Charpentier, E., Doudna, J.A., BIOTECHNOLOGY rewriting a genome. Nature 495 (2013), 50–51.
31. Cheng, A.W., et al. Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system. Cell Res. 23 (2013), 1163–1171.
32. Chesler, E.J., et al. Identification and ranking of genetic and laboratory environment factors influencing a behavioral trait, thermal nociception, via computational analysis of a large data archive. Neurosci. Biobehav. Rev. 26 (2002), 907–923.
33. Codita, A., et al. Impaired behavior of female tg-ArcSwe APP mice in the IntelliCage: a longitudinal study. Behav. Brain Res. 215 (2010), 83–94.
34. Codita, A., Effects of spatial and cognitive enrichment on activity pattern and learning performance in three strains of mice in the IntelliMaze. Behav Genet. 42 (2012), 449–460.
35. Collins, F.S., et al. A mouse for all reasons. Cell 128 (2007), 9–13.
36. Cong, L., et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339 (2013), 819–823.
37. Crabbe, J.C., et al. Genetics of mouse behavior: interactions with laboratory environment. Science 284 (1999), 1670–1672.
38. Crawley, J.N., Paylor, R., A proposed test battery and constellations of specific behavioral paradigms to investigate the behavioral phenotypes of transgenic and knockout mice. Horm. Behav. 31 (1997), 197–211.
39. Crestani, F., et al. Resolving differences in GABAA receptor mutant mouse studies. Nat. Neurosci., 3, 2000, 1059.
40. Domanskyi, A., et al. Prospects of neurotrophic factors for Parkinson's disease: comparison of protein and Gene therapy. Hum. Gene Ther. 26 (2015), 550–559.
41. Dreyer, J.L., New insights into the roles of microRNAs in drug addiction and neuroplasticity. Genome Med., 2, 2010, 92.
42. Eipper-Mains, J.E., et al. microRNA-Seq reveals cocaine-regulated expression of striatal microRNAs. RNA 17 (2011), 1529–1543.
43. Eipper-Mains, J.E., et al. Global approaches to the role of miRNAs in drug-induced changes in Gene expression. Front. Genet., 3, 2012, 109.
44. Endo, T., et al. Automated test of behavioral flexibility in mice using a behavioral sequencing task in IntelliCage. Behav. Brain Res. 221 (2011), 172–181.
45. Ernfors, P., et al. Mice lacking brain-derived neurotrophic factor develop with sensory deficits. Nature 368 (1994), 147–150.
46. Faghihi, M.A., et al. Evidence for natural antisense transcript-mediated inhibition of microRNA function. Genome Biol., 11, 2010, R56.
47. Faizi, M., et al. Comprehensive behavioral phenotyping of Ts65Dn mouse model of down syndrome: activation of beta(1)-adrenergic receptor by xamoterol as a potential cognitive enhancer. Neurobiol. Dis. 43 (2011), 397–413.
48. Galinato, M.H., et al. Methamphetamine differentially affects BDNF and cell death factors in anatomically defined regions of the hippocampus. Neuroscience 286 (2015), 97–108.
49. Gerlai, R., Gene-targeting studies of mammalian behavior: is it the mutation or the background genotype?. Trends Neurosci. 19 (1996), 177–181.
50. Ghitza, U.E., et al. Role of BDNF and GDNF in drug reward and relapse: a review. Neurosci. Biobehav. Rev. 35 (2010), 157–171.
51. Gilbert, L.A., et al. Genome-scale CRISPR-mediated control of Gene repression and activation. Cell 159 (2014), 647–661.
52. Gomez-Marin, A., et al. Big behavioral data: psychology, ethology and the foundations of neuroscience. Nat. Neurosci. 17 (2014), 1455–1462.
53. Green, A.S., Grahame, N.J., Ethanol drinking in rodents: is free-choice drinking related to the reinforcing effects of ethanol?. Alcohol 42 (2008), 1–11.
54. Green, T.A., et al. Environmental enrichment produces a behavioral phenotype mediated by low cyclic adenosine monophosphate response element binding (CREB) activity in the nucleus accumbens. Biol. Psychiatry 67 (2010), 28–35.
55. Grimm, J.W., et al. Neuroadaptation. Incubation of cocaine craving after withdrawal. Nature 412 (2001), 141–142.
56. Hamra, F.K., et al. Self renewal, expansion, and transfection of rat spermatogonial stem cells in culture. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 17430–17435.
57. He, D.Y., Ron, D., Autoregulation of glial cell line-derived neurotrophic factor expression: implications for the long-lasting actions of the anti-addiction drug, Ibogaine. FASEB J. 20 (2006), 2420–2422.
58. He, D.Y., et al. Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption. J. Neurosci. 25 (2005), 619–628.
59. Hebert, M.A., et al. Functional effects of GDNF in normal rat striatum: presynaptic studies using in vivo electrochemistry and microdialysis. J. Pharmacol. Exp. Ther. 279 (1996), 1181–1190.
60. Heikkinen, A.E., et al. Long-lasting modulation of glutamatergic transmission in VTA dopamine neurons after a single dose of benzodiazepine agonists. Neuropsychopharmacology 34 (2009), 290–298.
61. Henriques, A., et al. Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand?. Front. Neurosci., 4, 2010, 32.
62. Heyer, M.P., Kenny, P.J., Corticostriatal microRNAs in addiction. Brain Res., 2015.
63. Hollander, J.A., et al. Striatal microRNA controls cocaine intake through CREB signalling. Nature 466 (2010), 197–202.
64. Huang, Y.W., et al. Dual regulation of miRNA biogenesis generates target specificity in neurotrophin-induced protein synthesis. Cell 148 (2012), 933–946.
65. Hudson, J., et al. Glial cell line-derived neurotrophic factor augments midbrain dopaminergic circuits in vivo. Brain Res. Bull. 36 (1995), 425–432.
66. Hunt, W.A., et al. Relapse rates in addiction programs. J. Clin. Psychol. 27 (1971), 455–456.
67. Hyman, C., et al. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 350 (1991), 230–232.
68. Ickes, B.R., et al. Long-term environmental enrichment leads to regional increases in neurotrophin levels in rat brain. Exp. Neurol. 164 (2000), 45–52.
69. Im, H.I., Kenny, P.J., MicroRNAs in neuronal function and dysfunction. Trends Neurosci. 35 (2012), 325–334.
70. Im, H.I., et al. MeCP2 controls BDNF expression and cocaine intake through homeostatic interactions with microRNA-212. Nat. Neurosci. 13 (2010), 1120–1127.
71. Izsvak, Z., et al. Generating knockout rats by transposon mutagenesis in spermatogonial stem cells. Nat. Methods 7 (2010), 443–445.
72. Jain, S., et al. RET is dispensable for maintenance of midbrain dopaminergic neurons in adult mice. J. Neurosci. 26 (2006), 11230–11238.
73. Jeanblanc, J., et al. The dopamine D3 receptor is part of a homeostatic pathway regulating ethanol consumption. J. Neurosci. 26 (2006), 1457–1464.
74. Jeanblanc, J., et al. BDNF-mediated regulation of ethanol consumption requires the activation of the MAP kinase pathway and protein synthesis. Eur. J. Neurosci. 37 (2013), 607–612.
75. Jia, H., et al. Genome-wide computational identification and manual annotation of human long noncoding RNA genes. RNA 16 (2010), 1478–1487.
76. Jinek, M., et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337 (2012), 816–821.
77. Kang, H., Schuman, E.M., Long-lasting neurotrophin-induced enhancement of synaptic transmission in the adult hippocampus. Science 267 (1995), 1658–1662.
78. Kauer, J.A., Malenka, R.C., Synaptic plasticity and addiction. Nat. Rev. Neurosci. 8 (2007), 844–858.
79. Kim, J., et al. A MicroRNA feedback circuit in midbrain dopamine neurons. Science 317 (2007), 1220–1224.
80. Knapska, E., et al. Differential involvement of the central amygdala in appetitive versus aversive learning. Learn. Mem. 13 (2006), 192–200.
81. Knapska, E., et al. Reward learning requires activity of matrix metalloproteinase-9 in the central amygdala. J. Neurosci. 33 (2013), 14591–14600.
82. Kobayashi, Y., et al. Genetic dissection of medial habenula-interpeduncular nucleus pathway function in mice. Front. Behav. Neurosci., 7, 2013, 17.
83. Konopka, W., et al. MicroRNA loss enhances learning and memory in mice. J. Neurosci. 30 (2010), 14835–14842.
84. Koo, J.W., et al. BDNF is a negative modulator of morphine action. Science 338 (2012), 124–128.
85. Koo, J.W., et al. Epigenetic basis of opiate suppression of Bdnf gene expression in the ventral tegmental area. Nat. Neurosci. 18 (2015), 415–422.
86. Kopra, J., et al. GDNF is not required for catecholaminergic neuron survival in vivo. Nat. Neurosci. 18 (2015), 319–322.
87. Krackow, S., Consistent behavioral phenotype differences between inbred mouse strains in the IntelliCage. Genes Brain Behav. 9 (2010), 722–731.
88. Kramer, E.R., et al. Absence of Ret signaling in mice causes progressive and late degeneration of the nigrostriatal system. PLoS Biol., 5, 2007, e39.
89. Kreek, M.J., et al. Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction. Nat. Neurosci. 8 (2005), 1450–1457.
90. Krol, J., et al. The widespread regulation of microRNA biogenesis, function and decay. Nat. Rev. Genet. 11 (2010), 597–610.
91. Kulesskaya, N., et al. Mixed housing with DBA/2 mice induces stress in C57BL/6 mice: implications for interventions based on social enrichment. Front. Behav. Neurosci., 8, 2014, 257.
92. Kumar, A., et al. GDNF overexpression from the native locus reveals its role in the nigrostriatal dopaminergic system function. PLoS Genet., 2015 (in press).
93. Li, P., et al. Germline competent embryonic stem cells derived from rat blastocysts. Cell 135 (2008), 1299–1310.
94. Li, L., et al. NCAM signaling mediates the effects of GDNF on chronic morphine-induced neuroadaptations. J. Mol. Neurosci. 53 (2014), 580–589.
95. Li, X., et al. Incubation of methamphetamine craving is associated with selective increases in expression of Bdnf and trkb, glutamate receptors, and epigenetic enzymes in cue-activated fos-expressing dorsal striatal neurons. J. Neurosci. 35 (2015), 8232–8244.
96. Lin, L.F., et al. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260 (1993), 1130–1132.
97. Lipp, H.P., Wolfer, D.P., Genetically modified mice and cognition. Curr. Opin. Neurobiol. 8 (1998), 272–280.
98. Lipp, H.P., Wolfer, D.P., Genetic background problems in the analysis of cognitive and neuronal changes in genetically modified mice. Clin. Neurosci. Res. 3 (2003), 223–231.
99. Liss, B., Roeper, J., Individual dopamine midbrain neurons: functional diversity and flexibility in health and disease. Brain Res. Rev. 58 (2008), 314–321.
100. Logrip, M.L., et al. Dynorphin is a downstream effector of striatal BDNF regulation of ethanol intake. FASEB J. 22 (2008), 2393–2404.
101. Logrip, M.L., et al. Escalating ethanol intake is associated with altered corticostriatal BDNF expression. J. Neurochem. 109 (2009), 1459–1468.
102. Lohof, A.M., et al. Potentiation of developing neuromuscular synapses by the neurotrophins NT-3 and BDNF. Nature 363 (1993), 350–353.
103. Lu, L., et al. A single infusion of brain-derived neurotrophic factor into the ventral tegmental area induces long-lasting potentiation of cocaine seeking after withdrawal. J. Neurosci. 24 (2004), 1604–1611.
104. Lu, L., et al. Incubation of cocaine craving after withdrawal: a review of preclinical data. Neuropharmacology 47:Suppl. 1 (2004), 214–226.
105. Lu, L., et al. Role of ventral tegmental area glial cell line-derived neurotrophic factor in incubation of cocaine craving. Biol. Psychiatry 66 (2009), 137–145.
106. Luscher, C., Malenka, R.C., Drug-evoked synaptic plasticity in addiction: from molecular changes to circuit remodeling. Neuron 69 (2011), 650–663.
107. Mameli, M., Luscher, C., Synaptic plasticity and addiction: learning mechanisms gone awry. Neuropharmacology 61 (2011), 1052–1059.
108. Manning, E.E., et al. BDNF-deficient mice show reduced psychosis-related behaviors following chronic methamphetamine. Int. J. Neuropsychopharmacol., 2015.
109. McGinty, J.F., et al. The role of BDNF/TrkB signaling in acute amphetamine-induced locomotor activity and opioid peptide Gene expression in the rat dorsal striatum. Front. Syst. Neurosci., 5, 2011, 60.
110. McIlwain, K.L., et al. The use of behavioral test batteries: effects of training history. Physiol. Behav. 73 (2001), 705–717.
111. Messer, C.J., et al. Role for GDNF in biochemical and behavioral adaptations to drugs of abuse. Neuron 26 (2000), 247–257.
112. Mijakowska, Z., et al. Autophosphorylation of alpha isoform of calcium/calmodulin-dependent kinase II regulates alcohol addiction-related behaviors. Addict. Biol., 2015.
113. Modarresi, F., et al. Inhibition of natural antisense transcripts in vivo results in gene-specific transcriptional upregulation. Nat. Biotechnol. 30 (2012), 453–459.
114. Moore, D.J., et al. Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci. 28 (2005), 57–87.
115. Mucha, R.F., et al. Drug reinforcement studied by the use of place conditioning in rat. Brain Res. 243 (1982), 91–105.
116. Mufson, E.J., et al. Intrastriatal infusions of brain-derived neurotrophic factor: retrograde transport and colocalization with dopamine containing substantia nigra neurons in rat. Exp. Neurol. 129 (1994), 15–26.
117. Nestler, E.J., Molecular basis of long-term plasticity underlying addiction. Nat. Rev. Neurosci. 2 (2001), 119–128.
118. Niwa, M., et al. The roles of glial cell line-derived neurotrophic factor, tumor necrosis factor-alpha, and an inducer of these factors in drug dependence. J. Pharmacol. Sci. 104 (2007), 116–121.
119. Nosrat, C.A., et al. Cellular and developmental patterns of expression of Ret and glial cell line-derived neurotrophic factor receptor alpha mRNAs. Exp. Brain Res. 115 (1997), 410–422.
120. Numan, S., Seroogy, K.B., Expression of trkB and trkC mRNAs by adult midbrain dopamine neurons: a double-label in situ hybridization study. J. Comp. Neurol. 403 (1999), 295–308.
121. Oo, T.F., et al. Regulation of natural cell death in dopaminergic neurons of the substantia nigra by striatal glial cell line-derived neurotrophic factor in vivo. J. Neurosci. 23 (2003), 5141–5148.
122. Paratcha, G., et al. The neural cell adhesion molecule NCAM is an alternative signaling receptor for GDNF family ligands. Cell 113 (2003), 867–879.
123. Parker, C.C., et al. Rats are the smart choice: rationale for a renewed focus on rats in behavioral genetics. Neuropharmacology 76 (2014), 250–258 (Pt B).
124. Parkitna, J.R., et al. Novelty-seeking behaviors and the escalation of alcohol drinking after abstinence in mice are controlled by metabotropic glutamate receptor 5 on neurons expressing dopamine D1 receptors. Biol. Psychiatry 73 (2013), 263–270.
125. Pascual, A., et al. Absolute requirement of GDNF for adult catecholaminergic neuron survival. Nat. Neurosci. 11 (2008), 755–761.
126. Patrikainen, M., et al. The role of carbonic anhydrase VI in bitter taste perception: evidence from the Car6 −/− mouse model. J. Biomed. Sci., 21, 2014, 82.
127. Peregud, D.I., et al. Expression of BDNF and TrkB Phosphorylation in the rat frontal cortex during morphine withdrawal are no dependent. Cell. Mol. Neurobiol., 2015.
128. Pickens, C.L., et al. Neurobiology of the incubation of drug craving. Trends Neurosci. 34 (2011), 411–420.
129. Pierce, R.C., Bari, A.A., The role of neurotrophic factors in psychostimulant-induced behavioral and neuronal plasticity. Rev. Neurosci. 12 (2001), 95–110.
130. Platt, R.J., et al. CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell 159 (2014), 440–455.
131. Pruunsild, P., et al. Dissecting the human BDNF locus: bidirectional transcription, complex splicing, and multiple promoters. Genomics 90 (2007), 397–406.
132. Puscian, A., et al. A novel automated behavioral test battery assessing cognitive rigidity in two genetic mouse models of autism. Front. Behav. Neurosci., 8, 2014, 140.
133. Radwanska, K., Kaczmarek, L., Characterization of an alcohol addiction-prone phenotype in mice. Addict. Biol. 17 (2012), 601–612.
134. Ran, F.A., et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 154 (2013), 1380–1389.
135. Rangasamy, S.B., et al. Neurotrophic factor therapy for Parkinson's disease. Prog. Brain Res. 184 (2010), 237–264.
136. Ren, Q., et al. 7,8-Dihydroxyflavone, a TrkB agonist, attenuates behavioral abnormalities and neurotoxicity in mice after administration of methamphetamine. Psychopharmacology 231 (2014), 159–166.
137. Richardson, C.A., The power of automated behavioural homecage technologies in characterizing disease progression in laboratory mice: a review. Appl. Anim. Behav. Sci. 163 (2015), 19–27.
138. Ron, D., Janak, P.H., GDNF and addiction. Rev. Neurosci. 16 (2005), 277–285.
139. Rosenthal, N., Brown, S., The mouse ascending: perspectives for human-disease models. Nat. Cell Biol. 9 (2007), 993–999.
140. Rossi, C., et al. Brain-derived neurotrophic factor (BDNF) is required for the enhancement of hippocampal neurogenesis following environmental enrichment. Eur. J. Neurosci. 24 (2006), 1850–1856.
141. Russo, S.J., et al. Neurotrophic factors and structural plasticity in addiction. Neuropharmacology 56:Suppl. 1 (2009), 73–82.
142. Ryan, D., et al. Spatial learning impairments in PLB1 knock-in Alzheimer mice are task-specific and age-dependent. Cell. Mol. Life Sci. 70 (2013), 2603–2619.
143. Saal, D., et al. Drugs of abuse and stress trigger a common synaptic adaptation in dopamine neurons. Neuron 37 (2003), 577–582.
144. Salmena, L., et al. A ceRNA hypothesis: the Rosetta stone of a hidden RNA language?. Cell 146 (2011), 353–358.
145. Schratt, G., microRNAs at the synapse. Nat. Rev. Neurosci. 10 (2009), 842–849.
146. Schulte-Herbruggen, O., et al. Neurotrophins: from pathophysiology to treatment in Alzheimer's disease. Curr. Alzheimer Res. 5 (2008), 38–44.
147. Seroogy, K.B., et al. Dopaminergic neurons in rat ventral midbrain express brain-derived neurotrophic factor and neurotrophin-3 mRNAs. J. Comp. Neurol. 342 (1994), 321–334.
148. Shaham, Y., et al. The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology 168 (2003), 3–20.
149. Shalev, U., et al. Neurobiology of relapse to heroin and cocaine seeking: a review. Pharmacol. Rev. 54 (2002), 1–42.
150. Shao, Y., et al. CRISPR/Cas-mediated genome editing in the rat via direct injection of one-cell embryos. Nat. Protoc. 9 (2014), 2493–2512.
151. Shen, R.Y., et al. Brain-derived neurotrophic factor increases the electrical activity of pars compacta dopamine neurons in vivo. Proc. Natl. Acad. Sci. U. S. A. 91 (1994), 8920–8924.
152. Shen, F., et al. Amphetamine-induced place preference and conditioned motor sensitization requires activation of tyrosine kinase receptors in the hippocampus. J. Neurosci. 26 (2006), 11041–11051.
153. Silva, A.J., et al. Mutant mice and neuroscience: recommendations concerning genetic background. Banbury Conference on genetic background in mice. Neuron 19 (1997), 755–759.
154. Smutek, M., et al. A model of alcohol drinking under an intermittent access schedule using group-housed mice. PLoS ONE, 9, 2014, e96787.
155. Sousa, N., et al. A hitchhiker's guide to behavioral analysis in laboratory rodents. Genes Brain Behav. 5:Suppl. 2 (2006), 5–24.
156. Spanagel, R., Weiss, F., The dopamine hypothesis of reward: past and current status. Trends Neurosci. 22 (1999), 521–527.
157. Spruijt, B.M., DeVisser, L., Advanced behavioural screening: automated home cage ethology. Drug Discovery Today: Technologies 3 (2006), 231–237.
158. Stragier, E., et al. Ethanol-induced epigenetic regulations at the Bdnf gene in C57BL/6J mice. Mol. Psychiatry 20 (2015), 405–412.
159. Sumazin, P., et al. An extensive microRNA-mediated network of RNA-RNA interactions regulates established oncogenic pathways in glioblastoma. Cell 147 (2011), 370–381.
160. Swiech, L., et al. In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat. Biotechnol. 33 (2015), 102–106.
161. Tan, K.R., et al. Neural bases for addictive properties of benzodiazepines. Nature 463 (2010), 769–774.
162. Tapocik, J.D., et al. microRNA-206 in rat medial prefrontal cortex regulates BDNF expression and alcohol drinking. J. Neurosci. 34 (2014), 4581–4588.
163. Tecott, L.H., Nestler, E.J., Neurobehavioral assessment in the information age. Nat. Neurosci. 7 (2004), 462–466.
164. Tomac, A., et al. Retrograde axonal transport of glial cell line-derived neurotrophic factor in the adult nigrostriatal system suggests a trophic role in the adult. Proc. Natl. Acad. Sci. U. S. A. 92 (1995), 8274–8278.
165. Ungerstedt, U., Stereotaxic mapping of the monoamine pathways in the rat brain. Acta Physiol. Scand. Suppl. 367 (1971), 1–48.
166. Ungless, M.A., et al. Single cocaine exposure in vivo induces long-term potentiation in dopamine neurons. Nature 411 (2001), 583–587.
167. Valzelli, L., The “isolation syndrome” in mice. Psychopharmacologia 31 (1973), 305–320.
168. van Dijk, R.M., Large-scale phenotyping links adult hippocampal neurogenesis to the reaction to novelty. Hippocampus. 26 (2016), 646–657.
169. Vannoni, E., et al. Spontaneous behavior in the social homecage discriminates strains, lesions and mutations in mice. J. Neurosci. Methods 234 (2014), 26–37.
170. Varendi, K., et al. From microRNA target validation to therapy: lessons learned from studies on BDNF. Cell. Mol. Life Sci. 72 (2015), 1779–1794.
171. Vargas-Perez, H., et al. Ventral tegmental area BDNF induces an opiate-dependent-like reward state in naive rats. Science 324 (2009), 1732–1734.
172. Veremieva, M., et al. Using IntelliCage to study alcohol drinking behavior in mice. Society for Neuroscience meeting Chicago, IL, USA, October 17–21, 2015.
173. Vinnikov, I.A., et al. Hypothalamic miR-103 protects from hyperphagic obesity in mice. J. Neurosci. 34 (2014), 10659–10674.
174. Voikar, V., et al. Behavioral alterations induced by repeated testing in C57BL/6J and 129S2/Sv mice: implications for phenotyping screens. Genes Brain Behav. 3 (2004), 27–38.
175. Voikar, V., et al. Long-term individual housing in C57BL/6J and DBA/2 mice: assessment of behavioral consequences. Genes Brain Behav. 4 (2005), 240–252.
176. Wagner, F.A., Anthony, J.C., From first drug use to drug dependence; developmental periods of risk for dependence upon marijuana, cocaine, and alcohol. Neuropsychopharmacology 26 (2002), 479–488.
177. Wan, L., et al. RACK1 affects morphine reward via BDNF. Brain Res. 1416 (2011), 26–34.
178. Wang, H., et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 153 (2013), 910–918.
179. Weeks, J.R., Experimental morphine addiction: method for automatic intravenous injections in unrestrained rats. Science 138 (1962), 143–144.
180. Weyer, S.W., et al. APP and APLP2 are essential at PNS and CNS synapses for transmission, spatial learning and LTP. EMBO J. 30 (2011), 2266–2280.
181. Wikler, A., Dynamics of drug dependence. Implications of a conditioning theory for research and treatment. Arch. Gen. Psychiatry 28 (1973), 611–616.
182. Wise, R.A., Rompre, P.P., Brain dopamine and reward. Annu. Rev. Psychol. 40 (1989), 191–225.
183. Wolfer, D.P., et al. Knockout mice: simple solutions to the problems of genetic background and flanking genes. Trends Neurosci. 25 (2002), 336–340.
184. Yamamoto, S., et al. Efficient gene-targeting in rat embryonic stem cells by CRISPR/Cas and generation of human kynurenine aminotransferase II (KAT II) knock-in rat. Transgenic Res. 24 (2015), 991–1001.
185. Yang, H., et al. One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering. Cell 154 (2013), 1370–1379.
186. Ying, Q.L., et al. The ground state of embryonic stem cell self-renewal. Nature 453 (2008), 519–523.
187. Yoneyama, N., et al. Voluntary ethanol consumption in 22 inbred mouse strains. Alcohol 42 (2008), 149–160.